A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Subjects With Advanced Solid Tumors
The primary objectives of this study are to characterize the safety and tolerability of GS-3583 as monotherapy, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Advanced Solid Tumors
Gender
N/A
Date
March 2021 - November 2022
Study Type
Interventional
Study Phase
Phase 1
Product
GS-3583
Grand Rapids, Michigan, United States, 49546
New York, New York, United States, 10029
Portland, Oregon, United States, 97239
San Antonio, Texas, United States, 78229
Share Trial